BPMC Blueprint Medicines Corp

For the fiscal year ended 31/12/2022: Blueprint Medicines Corp's revenues increased by 13.30% and amounted to 204.04M. Net income increased by 13.44% to -557.52M. Net assets increased by 9.54% to 1.33B and EPS increased from -11.01 to -9.35.